key: cord-0805379-i1x7n5vh
authors: Debie, Y.; Vandamme, T.; Goossens, M.E.; van Dam, P.A.; Peeters, M.
title: Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer patients
date: 2021-12-29
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.12.025
sha: 49d45b4adcbbccbd3b65ad77538ab93c5fe3d8c8
doc_id: 805379
cord_uid: i1x7n5vh

nan

Cancer patients are at increased risk for severe COVID-19 and have reduced humoral immune responses after SARS-CoV-2 infection and dual-dose BNT162b2 vaccination 1,2 . Recently it was observed that a third dose of BNT162b2 is able to elicit higher SARS-CoV-2 anti-receptor-binding domain (RBD) IgG titers in solid-organ transplant patients and adults aged ≥60 years compared to two doses 3, 4 . Initial reports with limited sample size, also indicated that the a third BNT162b2 vaccination dose would be beneficial for solid tumor patients receiving active anti-neoplastic treatment [5] [6] [7] . The current study (B-VOICE: EudraCT 2021-000300-38), which is the first large-scale prospective study on humoral responses after a third dose six months post primo vaccination in cancer patients, confirms that most cancer patients will elicit a higher humoral response after a third dose of BNT162b2. Quantitative analysis of IgG-antibodies against the SARS-CoV-2 RBD antigen by enzyme-linked immunosorbent assay (ELISA) was performed before first dose, 28 days and six months after second dose and 28 days after third BNT162b2 dose in 141 oncohematological patients (Suppl . Table 1 ). From the 200 initial participants that were included in the B-VOICE study 2 , 141 were evaluable after third dose. Drop-out was due to demise (20 participants, 10.0%), postponed vaccination due to illness or disease progression (8 participants, 4.0%), vaccination outside study protocol (5 participants, 2.5%) and consent withdrawal (26 participants, 13.0%).

All subjects were assigned to a cohort based on the treatment type receiving at time of the third dose administration. Subjects with a solid tumor were divided into four treatment cohorts: chemotherapy, immunotherapy, targeted/hormonal therapy and chemotherapy + immunotherapy.

A differentiation for patients with hematological malignancies was made between patients receiving rituximab and patients who have had undergone hematopoietic stem cell transplantation (HSCT) more than one year ago. An additional cohort was created for 7 subjects with hematological malignancy and 13 subjects with solid tumors that were no longer receiving active therapy at the time of third dose. A third BNT162b2 vaccination dose was administered 183 ± 10 days (6 months) for 97% and 169-200 days for 3% of the subjects, after administration of the second BNT162b2 dose. 

Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

Waning Immune Humoral Response to BNT162b2 Covid-19

Vaccine over 6 Months

Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine

Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab

IgG antibody titers 28 days and six months after second BNT162b2 dose and 28 days after third BNT162b2 mRNA COVID-19 vaccine in the different treatment cohorts. Subjects were assigned to treatment cohorts based on the therapy received at time of the third dose. The height of each bar represents the geometric mean titer (GMT)

We kindly thank the B-VOICE patients for participation, the nursing staff members at the Day Care Unit of the Antwerp University Hospital, the staff members of the Biobank Antwerp and all recruiting physicians. We are grateful to Dr. Ella Roelant